Tuesday, May 30th | 5 Sivan 5777

Close

Be in the know!

Get our exclusive daily news briefing.

Subscribe
April 22, 2015 10:54 am

Israel’s Teva Seeks to Acquire Drug Manufacturer Mylan for $40 Billion

avatar by JNS.org

Email a copy of "Israel’s Teva Seeks to Acquire Drug Manufacturer Mylan for $40 Billion" to a friend

Teva's acquisition of Mylan N.V would help Teva eliminate some competition for its Copaxone drug, a revolutionary treatment for Multiple Sclerosis. Photo: Teva.

JNS.org – The Israeli pharmaceutical giant Teva has made a $40 billion offer for the drug manufacturer Mylan N.V. If the acquisition goes through, it will be the largest Israeli business deal ever.

The two companies would have a combined 400 short-listed drug requests with the US Food and Drug Administration, and another 80 submitted for the first time. According to estimates, the acquisition would allow Teva to eliminate some of the rising competition for the multiple sclerosis drug Copaxone, because Mylan has developed a rival version of Teva’s successful medication.

Related coverage

May 29, 2017 11:02 am
0

Israeli Researchers Develop New ALS Treatment

JNS.org - Researchers at Israel’s Ben-Gurion University of the Negev (BGU) announced the development of a new treatment for amyotrophic lateral...

The companies’ combined revenue would comprise some $30 billion annually, and their earnings before interest, taxes, depreciation, and amortization would stand at some $9 billion per year. Teva estimates that the deal could save both companies $2 billion per year through efficiency measures and tax benefits.

Teva CEO Erez Vigodman said he was certain that a merger would provide “strategic and financial advantages for both companies.” But Mylan expressed reluctance to go through with the deal, saying in a press release that it has examined the proposal and believes “it is clear that such a combination is without sound industrial logic or cultural fit.”

Share this Story: Share On Facebook Share On Twitter Email This Article

Let your voice be heard!

Join the Algemeiner

Algemeiner.com